TNF-blockade in patients with advanced hormone refractory prostate cancer

被引：5
作者：
Diaz, Luis A., Jr. [1 ,2 ]
Messersmith, Wells [3 ]
Sokoll, Lori [2 ,4 ]
Sinibaldi, Vicki [2 ]
Moore, Sandy [2 ]
Carducci, Michael [2 ]
Eisenberger, Mario [2 ]
机构：
[1] Ludwig Ctr Canc Genet & Therapeut Johns Hopkins, Baltimore, MD 21231 USA
[2] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD 21231 USA
[3] Univ Colorado, Div Med Oncol, Ctr Canc, Aurora, CO 80045 USA
[4] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21231 USA
来源：
INVESTIGATIONAL NEW DRUGS | 2011年 / 29卷 / 01期
关键词：
Prostate cancer; Hormone refractory; TNF-alpha; Infliximab; IL-6; INTERLEUKIN-6; PATHWAY; GROWTH;
D O I：
10.1007/s10637-009-9346-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：192 / 194
页数：3
相关论文
共 50 条
  • [41] Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer
    Nelius, T
    Reiher, F
    Lindenmeir, T
    Klatte, T
    Rau, O
    Burandt, J
    Filleur, S
    Allhoff, EP
    ONKOLOGIE, 2005, 28 (11): : 573 - 578
  • [42] RADIOTHERAPY FOR REGIONALLY LOCALIZED HORMONE-REFRACTORY PROSTATE-CANCER
    LANKFORD, SP
    POLLACK, A
    ZAGARS, GK
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 33 (04): : 907 - 912
  • [43] Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: The argument for
    Debruyne, FMJ
    EUROPEAN UROLOGY, 1996, 29 : 34 - 36
  • [44] Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy
    Berry, W
    Eisenberger, M
    ONCOLOGIST, 2005, 10 : 30 - 39
  • [45] Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients
    Bertelli, G
    Heouaine, A
    Arena, G
    Botto, A
    Garrone, O
    Colantonio, I
    Occelli, M
    Fea, E
    Giubergia, S
    Merlano, M
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (01) : 46 - 51
  • [46] Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients
    Prezioso, Domenico
    Galasso, Raffaele
    Di Martino, Mario
    Iapicca, Gennaro
    Annunziata, Emanuele
    Iacono, Fabrizio
    ANTICANCER RESEARCH, 2007, 27 (02) : 1095 - 1104
  • [47] Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients
    Berruti, A
    Mosca, A
    Bitossi, R
    Gorzegno, G
    Guercio, S
    Poggio, M
    Tampellini, M
    Porpiglia, F
    Ostellino, O
    Scarpa, RM
    Dogliotti, L
    ANTICANCER RESEARCH, 2005, 25 (6C) : 4475 - 4479
  • [48] Efficacy of irradiation and external hyperthermia in locally advanced, hormone-refractory or radiation recurrent prostate cancer: A preliminary report
    Kalapurakal, JA
    Pierce, M
    Chen, A
    Sathiaseelan, V
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03): : 654 - 664
  • [49] Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer
    Huan, SD
    Stewart, DJ
    Aitken, SE
    Segal, R
    Yau, JC
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05): : 471 - 474
  • [50] Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade
    Strum, SB
    McDermed, JE
    Scholz, MC
    Johnson, H
    Tisman, G
    BRITISH JOURNAL OF UROLOGY, 1997, 79 (06): : 933 - 941
12345